GAP214
GAP214 is a monosaccharide lipid A analogue and TLR4/MD-2 complex modulator.GAP214 binds to the TLR4/MD-2 complex via hydrophobic interactions, salt bridges, and hydrogen bonds, induces dimerization of the complex to initiate intracellular signaling cascades.GAP214 functions as an immunostimulant and vaccine adjuvant, enhances antigen-specific IgG antibody production in a mouse model.
For research use only. We do not sell to patients.
- Formula: C95H182N3O19P
- Molecular Weight:1701.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
TLR4 |
GAP214 potently activates murine DC2.4 dendritic cells via the TLR4 pathway, inducing 3.5-fold higher IL-6 and 4.7-fold higher IL-12p70 secretion than PHAD, and increasing CD80+CD86+ double-positive cells to 17.98%[1].
GAP214 potently activates murine RAW264.7 macrophages via the TLR4 pathway, inducing higher IL-6 and TNF-α secretion than PHAD, and increasing CD80+CD86+ double-positive cells to 14.47%[1].
GAP214 potently activates human THP-1 monocytic cells, inducing higher IL-6 and TNF-α secretion than PHAD[1].
GAP214 (10-100 μg/mL; 24 h) exhibits no significant cytotoxicity against HEK293 or B16F10 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 6-8 weeks old, 5 mice per group)[1]
-
Dosage:17 μg per mouse per immunization (formulated into liposomes with DSPC:cholesterol:GAP214 molar ratio 5:4:1)
-
Administration:intraperitoneal injection; 3 doses at 2-week intervals
-
Result:Induced IgG antibody titers 3.3-fold higher than PHAD-adjuvanted control after first immunization (Day 14).
Induced IgG antibody titers 2.5-fold higher than PHAD-adjuvanted control after third immunization (Day 42).
Exhibited highest serum IL-6 levels among adjuvant groups at 2 hours post-immunization.
Promoted maturation and activation of dendritic cells, with 24.60% CD80+CD86+ DCs in spleen and 10.30% CD80+CD86+ DCs in draining lymph nodes after two immunizations and 3 days of observation.
Induced 5.88% IFN-γ+TNF-α+ CD4+ T cells and 4.92% IFN-γ+TNF-α+ CD8+ T cells in splenocytes, the highest among adjuvant groups.
Induced 12.03% CD4+ central memory T cells and 19.52% CD8+ central memory T cells in spleen, which were 1.5-fold and 2.5-fold higher than PHAD-adjuvanted control, respectively.
Chemical Information
-
Molecular Weight 1701.44
-
Formula C95H182N3O19P
-
SMILES
OC[C@@H]1[C@@H](OP(O)(O)=O)C(OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@@H](NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@H](OCC(CNC(C[C@H](O)CCCCCCCCCCC)=O)(CNC(C[C@H](O)CCCCCCCCCCC)=O)CO)O1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GAP214 Related Classifications
HY-182034 Related Classifications
Powered by Bioz